ckd

CKD-519 is a selective inhibitor of cholesteryl ester transfer protein (CETP). It inhibits CETP-mediated transfer of cholesteryl ester in human serum (IC50: 2.3 nM).

R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor.

NS-3-008 hydrochloride (NS-3-008 HCl) is a transcriptional G0/G1 switch 2 (G0s2) inhibitor( IC50 of 2.25 μM).

Valecobulin hydrochloride (CKD-516 hydrochloride) is the valine prodrug and vasoblocker of S516. Valecobulin hydrochloride (CKD-516 hydrochloride) has a potent inhibitory effect on β-tubulin polymerization and has significant anti-tumor activity against solid tumors in mice and humans.

Valecobulin is a potent β-tubulin polymerization inhibitor. Valecobulin is a valine prodrug of (S516) and an avascular disrupting compound.

Beloranib is a fumagillin anticancer drug. Beloranib belongs to an angiogenesis inhibitor.

Lobeglitazone Sulfate(CKD-501 Sulfate) is a novel thiazolidinedione with anti-inflammatory activity that inhibits LPS-induced NLRP3 inflammasome activation and hepatic inflammation, and can be used in the study of type 2 diabetes mellitus (T2DM).

Tenofovir disoproxil aspartate, a nucleotide reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection.

Lobeglitazone, also known as CKD-501, is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.

Belotecan hydrochloride (CKD-602) is a synthetic water-soluble camptothecin derivative and topoisomerase I inhibitor with potential antitumor activity

CKD-731 is an analogue of Fumagillin. It inhibits the proliferation of bovine pulmonary artery endothelial cells, lymphoma EL-4 cells, and mouse leukemia P388D1 cells. CKD-731 functions by inhibiting MetAP-2 activity and blocking angiogenesis. It is applicable in studies related to angiogenesis-associated cancers.

CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC50 value of 78 μg/mL. It also inhibits porcine intestinal maltase and sucrase, with IC50 values of 2.5 and 0.5 μg/mL, respectively. CKD-711 exhibits selective antibacterial activity against Comamonas terrigena and is applicable in research on infections and metabolic disorders such as diabetes.

CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by suppressing cyclin A, cyclin B and C

Topoisomerase I inhibitor. Forms stable DNA-topoisomerase complexes during DNA replication and induces cell cycle arrest in the G2/M phase. Inhibits growth of a range of cancer cell lines in vitro, as well as of ovarian and leukemia tumors in vivo.

Lockdown is a reversible and non-competitive PPM1F inhibitor. Lockdown is selective for PPM1F, because this compound does not inhibit other protein phosphatases in vitro and does not induce additional phenotypes in PPM1F knockout cells. Lockdown acts in a dose-dependent, allosteric manner with high selectivity for PPM1F

MGCVQCKDKEA is an 11-residue membrane-anchoring motif derived from the Src kinase Fyn. It facilitates the expression of TMC1/2 proteins on the cell surface and can be utilized in the research of diseases related to inner ear mechanotransduction channels.

Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor with an IC50 of 151 nM. Entacapone is also a potential obesity-related gene (FTO) inhibitor that can inhibit FTO demethylation activity and be used in the study of metabolic diseases.

LG-PEG10-click-DBCO-Oleic is a polyethylene glycol (PEG) derivative used as a linker in the synthesis of Proteolysis Targeting Chimeras (PROTACs)[1].

DOPE (DOPE) is a neutral helper lipid for cationic liposomes.It is used in combination with cationic phospholipids to increase efficiency during DNA transfection studies as a non-viral method of gene delivery.

PROTACKDM4 degrader-1 (Compound 11) is a proteolysis-targeting chimera (PROTAC) degrader specifically designed for KDM4. It effectively degrades KDM4A-C while sparing KDM4D. In esophageal cancer cells, PROTACKDM4 degrader-1 demonstrates strong antiproliferative activity, inducing apoptosis and cell cycle arrest, and inhibits lysine demethylation of histone H3.

Lckdegrader-1 (Compound 17) is a molecular glue degrader that targets lymphocyte-specific protein tyrosine kinase (LCK) with a DC50 of 23.1 nM. It holds potential for research in T-cell acute lymphoblastic leukemia (T-ALL).

LCKdegrader-2 (Compound 17) is a Lck molecular glue degrader. It is applicable for research in cancers such as acute lymphoblastic leukemia (ALL).

LCKdegrader-3 (Compound 20) is a CRBN-based molecular glue degrader targeting LCK. It is applicable in the study of acute lymphoblastic leukemia.

PPACK Dihydrochloride is an efficient and selective irreversible thrombin inhibitor, which is often used in anticoagulant research, and can be used as a substitute anticoagulant for heparin lithium in blood gas and whole blood electrolyte analysis. PPACK is also used to regulate serine protease-related processes, which has application value in the study of thrombosis and fibrinolysis-related mechanisms.